Cash and Short Term Investments (Quarterly) Chart

View Cash and Short Term Investments (Quarterly) for VKTX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash and Short Term Investments (Quarterly) Chart
Start Trial

Historical Cash and Short Term Investments (Quarterly) Data

View and export this data back to 2014. Start Trial.
Date Value
June 30, 2026 501.66M
March 31, 2026 602.96M
December 31, 2025 705.74M
September 30, 2025 714.57M
June 30, 2025 807.72M
March 31, 2025 851.86M
December 31, 2024 902.61M
September 30, 2024 930.44M
June 30, 2024 942.26M
March 31, 2024 962.98M
December 31, 2023 362.08M
September 30, 2023 376.24M
June 30, 2023 392.92M
March 31, 2023 135.66M
December 31, 2022 155.48M
September 30, 2022 155.02M
June 30, 2022 168.92M
March 31, 2022 184.90M
December 31, 2021 202.10M
September 30, 2021 216.14M
June 30, 2021 228.26M
March 31, 2021 241.68M
December 31, 2020 248.39M
September 30, 2020 255.30M
June 30, 2020 263.00M
Date Value
March 31, 2020 269.16M
December 31, 2019 275.64M
September 30, 2019 288.07M
June 30, 2019 292.64M
March 31, 2019 298.72M
December 31, 2018 301.52M
September 30, 2018 304.16M
June 30, 2018 142.17M
March 31, 2018 77.47M
December 31, 2017 20.58M
September 30, 2017 9.839M
June 30, 2017 12.08M
March 31, 2017 12.31M
December 31, 2016 13.15M
September 30, 2016 14.62M
June 30, 2016 17.20M
March 31, 2016 11.25M
December 31, 2015 14.10M
September 30, 2015 17.49M
June 30, 2015 21.66M
March 31, 2015 0.327M
December 31, 2014
September 30, 2014
June 30, 2014 0.8915M
March 31, 2014 0.0788M

Cash and Short Term Investments Definition

Represents the sum of cash and short term investments.

Read full definition.

Cash and Short Term Investments (Quarterly) Range, Past 5 Years

View Cash and Short Term Investments (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash and Short Term Investments (Quarterly) Benchmarks

View Cash and Short Term Investments (Quarterly) Benchmarks
Start Trial
Vertex Pharmaceuticals, Inc. 7.863B
Eli Lilly & Co. 8.95B
Regeneron Pharmaceuticals, Inc. 8.005B
Skye Bioscience, Inc. 10.06M
Eledon Pharmaceuticals, Inc. 88.76M